H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $10 and keeps a Buy rating on the shares. The firm sees additional upside in taletrectinib.
Education
About Us
Working with TipRanks
Follow Us
1
H.C. Wainwright raised the firm’s price target on Nuvation Bio (NUVB) to $11 from $10 and keeps a Buy rating on the shares. The firm sees additional upside in taletrectinib.